Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”

Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17